Accurate Diagnosis and Treatment of Skin Cancer
Diagnostic Approach
For suspected melanoma, perform an urgent full-thickness excisional biopsy with 2-5 mm margins of normal skin and a cuff of subcutaneous fat—never use shave or punch biopsies as these prevent accurate Breslow thickness measurement and staging. 1, 2
Clinical Identification of Suspicious Lesions
Use the ABCDE criteria to identify concerning pigmented lesions: Asymmetry, Border irregularity, Color heterogeneity, Diameter >6 mm (though 38% of melanomas are ≤6 mm), and Evolution (change over time) 1, 3
Evolution is the most critical warning sign—recent changes in size, color, elevation, or texture should trigger immediate evaluation 2, 4
Apply the "ugly duckling" concept for nodular and atypical melanomas that may not meet ABCDE criteria but appear different from the patient's other moles 2, 4
Dermoscopy by experienced clinicians enhances diagnostic accuracy beyond naked-eye examination for both melanoma and keratinocyte carcinomas 1, 3
Urgent Referral Criteria
Refer patients with melanoma-suspicious lesions to a dermatologist or experienced surgeon within 2 weeks of identification 2
Document specific concerning features (darkening, enlargement, pruritus, raised/rough texture), exact anatomical location, and approximate size in the referral 2
Biopsy Technique Requirements
For Melanoma:
Full-thickness elliptical excisional biopsy is mandatory, encompassing the entire lesion with 2-5 mm lateral margins and deep subcutaneous fat 1, 2, 4
Orient the specimen longitudinally on extremities or along skin tension lines to facilitate potential re-excision 2
Preserve lymphatic drainage patterns to allow future sentinel lymph node biopsy if indicated 2
Avoid shave, punch, or incisional biopsies—these techniques preclude accurate Breslow thickness measurement and risk understaging 1, 2, 4
For Basal Cell and Squamous Cell Carcinoma:
Punch or shave biopsy extending into deep reticular dermis is acceptable for keratinocyte carcinomas when the lesion appears more than superficial 2
Include sufficient depth to assess for perineural invasion and deep soft tissue involvement 2
Essential Pathology Reporting Elements
The pathology report must include:
Breslow thickness in millimeters—the single most important prognostic factor for melanoma 1, 2
Ulceration status (present or absent)—critical for staging 1, 2
Mitotic rate (mitoses per mm²)—independent prognostic indicator 1, 2
Clark level of invasion—especially relevant for thin melanomas 2
Presence and extent of regression 1
Treatment Algorithms
Melanoma Treatment
Wide Local Excision Margins Based on Breslow Thickness:
Sentinel Lymph Node Biopsy:
Consider for lesions >0.8-1.0 mm thick or those with high-risk features (ulceration, high mitotic rate) 2
Provides accurate staging but has not demonstrated overall survival benefit 1
Should only be performed by skilled teams in experienced centers with appropriate consideration of morbidity versus benefit 1
Melanoma In Situ (Lentigo Maligna Type) Treatment Options
Surgical excision remains first-line treatment 1
Mohs micrographic surgery may be considered for staged surgery in cosmetically or functionally sensitive areas 1
Topical imiquimod 5% cream can be used for primary or adjuvant therapy: apply to the treatment area 5 times per week for 6 weeks, leaving on skin for approximately 8 hours before washing off 1, 5
Radiation therapy may be considered for patients who cannot undergo surgery 1
Basal Cell Carcinoma Treatment
Risk Stratification:
High-risk locations: "H-zone" or mask areas of face, head and neck region 2
High-risk size thresholds: ≥6 mm in high-risk facial locations, ≥10 mm in moderate-risk locations 2
Additional high-risk features: deep soft tissue involvement, bone involvement, perineural invasion 2
Treatment Options:
Surgical excision with appropriate margins based on risk stratification 1
Mohs micrographic surgery for high-risk lesions or cosmetically sensitive areas 1
Topical imiquimod 5% cream for superficial BCC: apply 5 times per week for 6 weeks to tumors ≤2 cm diameter on trunk, neck, or extremities (excluding hands/feet), with 1 cm margin around tumor 5
Radiation therapy, electrodesiccation and curettage, or photodynamic therapy for select cases 1
Squamous Cell Carcinoma Treatment
Surgical excision is the primary treatment modality 1
Mohs micrographic surgery for high-risk lesions 1
Radiation therapy may be used as primary or adjuvant treatment 1
Critical Pitfalls to Avoid
Never perform shave or punch biopsies on suspected melanoma—this is the most common error that prevents accurate staging 1, 2, 4
Do not rely solely on the 6 mm diameter criterion—many melanomas are smaller than 6 mm at diagnosis 4, 3
Do not dismiss symmetric, dome-shaped nodules—nodular melanomas often lack classic ABCDE features 4
Maintain low threshold for biopsy in high-risk populations (prior skin cancer, immunosuppression, genetic syndromes) 2
Do not extend treatment periods beyond recommended durations due to missed doses or rest periods 5
Post-Treatment Surveillance
Annual full-body skin examinations for life are mandatory after melanoma diagnosis due to significantly elevated risk of second primary melanoma 2
Educate patients on monthly self-examination techniques and sun-protection measures 2
Clinical clearance assessment for treated lesions should occur after resolution of local skin reactions (approximately 12 weeks post-treatment for topical therapies) 5
Any suspicious lesion arising in treatment area after clinical clearance requires immediate medical evaluation 5
Screening Considerations
Routine whole-body skin examination screening for asymptomatic average-risk adults has insufficient evidence regarding mortality or morbidity benefit 1
Primary care physicians demonstrate moderate accuracy in melanoma diagnosis with sensitivity 42-100% and specificity 70-98%, though most studies used images rather than whole-body examinations 1
Screening does identify thinner melanomas on average compared to usual care, but whether this translates to reduced mortality remains unproven 1